SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

2/27/24 10:33:04 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IPA alert in real time by email

SC 13G 1 ipa13gingsfeb2024.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. )* IMMUNOPRECISE ANTIBODIES LTD. ----------------------------------------------------- (Name of Issuer) COMMON STOCK ----------------------------------------------------- (Title of Class of Securities) 45257F200 ----------------------------------------------------- (CUSIP Number) 02/13/2024 ----------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [] Rule 13d-1(b) [X] Rule 13d-1(c) [] Rule 13d-1(d) ---------- *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 45257F200 -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON(S) I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) INGALLS & SNYDER LLC 135156620 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION UNITED STATES OF AMERICA -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER EACH 1,317,819 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER WITH 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 1,317,819 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,317,819 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.01% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON* ENTITY -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: IMMUNOPRECISE ANTIBODIES LTD -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 3204-4464 Markham St. Victoria, BC V8Z 7X8 Canada -------------------------------------------------------------- Item 2. (a) Name of Person Filing: CHRISTIAN C PARK -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: 1325 AVENUE OF THE AMERICAS, NEW YORK, NY 10019 C/O INGALLS AND SNYDER, LLC -------------------------------------------------------------- (c) Citizenship: USA -------------------------------------------------------------- (d) Title of Class of Securities: COMMON STOCK -------------------------------------------------------------- (e) CUSIP Number: 45257F200 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Rules 240.13d-(1), or 13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or Dealer registered under Section 15 of the Act, (15 U.S.C 78o) (b) [ ] Bank as defined in Section 3(a)(6) of the Act, (15 U.S.C 78c) (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act, (15 U.S.C 78c) (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8) (e) [X] Investment Adviser in accordance with Section 240.13d-1(b)(1)(ii)(E) (f) [ ] Employee Benefit Plan or endowment fund in accordance to Section 240.13d-1(b)(ii)(F) (g) [ ] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G) (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C 1813) (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C 80a-3) (j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J) Item 4. Ownership. (a) Amount beneficially owned: 1,317,819 (b) Percent of class: 5.01% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote 1,317,819 (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of 1,317,819 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following []. INAPPLICABLE Item 6. Ownership of More Than Five Percent on Behalf of Another Person. The Shares reported herein are not limited to, but include those of the personal accounts of William McHale, an advisor representative of the Reporting Person. All of the individuals are advisory clients of the Reporting Person. Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. INAPPLICABLE Item 8. Identification and Classification of Members of the Group. INAPPLICABLE Item 9. Notice of Dissolution of Group. INAPPLICABLE Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: 02/27/2024 BY: /s/ CHRISTIAN C PARK ---------------------------------- (Signature)* INGALLS & SNYDER LLC

Get the next $IPA alert in real time by email

Date

Price Target

Rating

Analyst

12/2/2022

$9.00

Buy

H.C. Wainwright

10/25/2021

$12.00

Buy

Benchmark

10/25/2021

$12.00

Buy

The Benchmark Company

SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

Chat with this insight

Recent Analyst Ratings for
$IPA

$IPA
Leadership Updates

Live Leadership Updates

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer

BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery

$IPA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on ImmunoPrecise Antibodies with a new price target

Benchmark initiated coverage on ImmunoPrecise Antibodies with a new price target

The Benchmark Company initiated coverage on ImmunoPrecise Antibodies with a new price target

$IPA
Press Releases

Fastest customizable press release news feed in the world

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology

$IPA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$IPA
SEC Filings